Literature DB >> 2467687

The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix.

R P Symonds1, R A Burnett, T Habeshaw, S B Kaye, M P Snee, E R Watson.   

Abstract

Forty patients with stage III and 15 patients with stage IVa carcinoma of cervix have been treated with two pulses of cisplatin, vincristine and bleomycin combination chemotherapy before full dose radical radiotherapy. Twenty-seven of 51 (53%, 95% confidence interval 40-67%) had an objective response to chemotherapy and all chemotherapy responders had a complete response to radiotherapy. The actuarial survival at 24 months of responders to chemotherapy is 71% against 37% for non-responders. The responding patients had an estimated reduction in mortality to 36% (P = 0.014, 95% CI 15-81%) of that of the non-responders to chemotherapy. The incidence of tumour recurrence or distant metastases showed a similar reduction to 34% (P = 0.006, 95% CI 14-73%) of that of the non-responders. The data strongly suggest that response to chemotherapy in the initial treatment of advanced cervical cancer is associated with an improvement in survival following subsequent radical radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467687      PMCID: PMC2247076          DOI: 10.1038/bjc.1989.98

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Pre-therapeutic experiments with the fast neutron beam from the Medical Research Council cyclotron. I. The biological and physical advantages and problems of neutron therapy.

Authors:  J F FOWLER; R L MORGAN; C A WOOD
Journal:  Br J Radiol       Date:  1963-02       Impact factor: 3.039

2.  Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer.

Authors:  F Kirsten; K H Atkinson; J V Coppleson; P M Elliott; D Green; R Houghton; J C Murray; P Russell; H J Solomon; M Friedlander
Journal:  Br J Obstet Gynaecol       Date:  1987-06

3.  Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix.

Authors:  E R Watson; K E Halnan; S Dische; M I Saunders; I S Cade; J B McEwen; G Wiernik; D J Perrins; I Sutherland
Journal:  Br J Radiol       Date:  1978-11       Impact factor: 3.039

4.  Patterns of spread of distant metastases in head and neck cancer.

Authors:  J C Probert; R W Thompson; M A Bagshaw
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

5.  Correlation of histopathology with clinical results following radiation therapy for carcinoma of the cervix.

Authors:  L L Gunderson; W S Weems; R M Herbertson; H P Plenk
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1974-01

6.  Time-dose and tumor volume relationships in the irradiation of squamous cell carcinoma of the tonsillar fossa.

Authors:  L J Shukovsky; G H Fletcher
Journal:  Radiology       Date:  1973-06       Impact factor: 11.105

7.  Cumulative radiation effect. II. Continuous radiation therapy--long-lived sources.

Authors:  J Kirk; W M Gray; E R Watson
Journal:  Clin Radiol       Date:  1972-01       Impact factor: 2.350

8.  A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.

Authors:  L E Kun; R J Toohill; P Y Holoye; J A Duncavage; R W Byhardt; P S Ritch; T W Grossman; R G Hoffmann; J D Cox; T Malin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-02       Impact factor: 7.038

Review 9.  Chemotherapy of cervical cancer.

Authors:  D Guthrie
Journal:  Clin Obstet Gynaecol       Date:  1985-03

10.  Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.

Authors:  J F Ensley; J R Jacobs; A Weaver; J Kinzie; J Crissman; J A Kish; G Cummings; M Al-Sarraf
Journal:  Cancer       Date:  1984-09-01       Impact factor: 6.860

View more
  1 in total

1.  Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.

Authors:  H Kühnle; H G Meerpohl; W Eiermann; S Röben; L Lenaz; W Achterrath
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.